VALGANCICLOVIR PRE-EMPTIVE THERAPY FOR CMV VIREMIA (ACTG A5030)

缬更昔洛韦预防巨细胞病毒血症 (ACTG A5030)

• 批准号: 7377410
• 负责人: DAVID A WOHL
• 金额: $ 6.64万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377410
• 关键词: VALGANCICLOVIR; PRE; EMPTIVE; THERAPY; CMV

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to find out whether treatment with valganciclovir is safe and effective in preventing CMV organ damage.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。本研究的目的是了解伐更昔洛韦治疗在预防CMV器官损伤方面是否安全有效。